Because of their arm's-length relationship with patients, pharmaceutical manufacturers have been interested in whether drug advertising can improve therapy compliance. Contrary to many industry surveys, the author finds that the impact is small in economic terms, the effect spills over to other brands, and, in certain cases, the effect may decrease average compliance rates.
Get full access to this article
View all access options for this article.
References
1.
BallingerMegan (2002), “Compliance Dwindles as Drug Costs Escalate,”Managed Healthcare Executive, 12(1), 7.
2.
BeaversNorma (1999), “Take as Directed,”Drug Topics, 18(143), 56–65.
3.
BowmanDouglas, HeilmanCarrie M., and (Seethu) SeetharamanP.B. (2004), “Determinants of Product Use Compliance Behavior,”Journal of Marketing Research, 41 (August), 324–38.
4.
CramerJoyce (2001), “The Usefulness of Medication Compliance Data in Interpretation of Outcomes,”ISPOR News, (October 15), 1, 3, 4.
5.
CramerJoyce, ScheyerR.D., and MattsonR.H. (1990), “Compliance Declines Between Clinic Visits,”Archives of Internal Medicine, 150(July), 1377–78.
6.
DalzellMichael (1999), “Pharmacy Copayments: A Double-Edged Sword,”Managed Care, 8(August), 26–31.
7.
DonohueJulie M., BerndtErnst R., RosenthalMeredith, EpsteinArnold M., and FrankRichard G. (2004), “Effects of Pharmaceutical Promotion on Adherence to the Treatment Guidelines for Depression,”Medical Care, 42(December), 1176–85.
8.
FinchamJack E., and WertheimerAlbert I. (1985), “Using the Health Belief Model to Predict Initial Drug Therapy Defaulting,”Social Science and Medicine, 20(1), 101–105.
9.
HawksJohn W., and LevyRichard A. (1993), “Boosting Script Yield: Health Rx for the Nineties,”Pharmaceutical Executive, 13(April), 44–51.
10.
IizukaToshiaki, and JinGinger Zhe (2005), “The Effects of Direct-to-Consumer Advertising on Doctor Visits,”Journal of Economics and Management Strategy, forthcoming.
JacksonRichard A., WorthenDennis B., and BarnettCandace W. (1998), “The Financial Aspects of Improved Refill Management,” in Practice Opportunities.Cincinnati: Procter & Gamble Health Care, 1–15.
15.
JohnsonJeffrey, and BootmanLyle (1995), “Drug Related Morbidity and Mortality in the United States,”Archives of Internal Medicine, 155(October), 1949–58.
16.
LodenJohn, and SchoolerCaroline (2000), “Patient Compliance,”Pharmaceutical Executive, 20(July), 88–94.
17.
ManningRichard, and KeithAlison (2001), “Prescription Drug Advertising: Empowering Consumers Through Information,”Economic Realities in Health Care Policy, 2(1), 8.
18.
NarayananSridhar, DesirajuRamarao, and ChintaguntaPradeep K. (2004), “Return on Investment Implications for Pharmaceutical Promotional Expenditures: The Role of Marketing-Mix Interactions,”Journal of Marketing, 68(October), 90–105.
19.
NeslinScott A. (2001), ROI Analysis of Pharmaceutical Promotion (RAPP), (accessed December 15, 2004), [available at http://www.rxpromoroi.org/rapp/].
20.
NIHCM Foundation (2000), Prescription Drugs and Mass Media Advertising, (September), (accessed December 14, 2004), [available at http://www.nihcm.org].
21.
O'BrienMary Kathryn, PetrieK., and RaeburnJ. (1992), “Adherence to Medication Regimens: Updating a Complex Medical Issue,”Medical Care Review, 49(4), 435–54.
RosenthalMeredith B., BerndtErnst R., DonohueJulie M., EpsteinArnold, and FrankRichard G. (2003), “Demand Effects of Recent Changes in Prescription Drug Promotion,”Frontiers in Health Policy Research, 6(June), 1–26.
24.
SabatéEduardo (2003), Adherence to Long-Term Therapies: Evidence for Action.Geneva, Switzerland: World Health Organization.
SmithDorothy L. (1999), “DTC Ads: Promoting Compliance a Win-Win Prospect,”Pharmaceutical Executive, 19(December), 84.
27.
SteenburghThomas J., and WittinkDick (2004), “Market-Source Decompositions of Demand,” working paper, Harvard Business School.
28.
StephensonBarbara J., RoweBrian H., Brian HaynesR., MachariaWilliam M., and LeonG. (1993), “The Rational Clinical Examination. Is This Patient Taking the Treatment as Prescribed?”Journal of American Medical Association, 269(June), 2779–81.
29.
SullivanSean D., KrelingDavid H., and HazletThomas K. (1990), “Non-Compliance with Medication Regimens and Subsequent Hospitalization: A Literature Analysis and Cost of Hospitalization Estimate,”Journal of Research in Pharmaceutical Economics, 2(2), 19–33.
30.
Van der PoolLisa (2003), “Omnicom Expands in Health Category,”AdWeek, 44(7), 12.
31.
WittinkDick R. (2002), “Analysis of ROI for Pharmaceutical Promotions,” (September), video presentation, The Association of Medical Publications, (accessed December 15, 2004), [available at http://www.vioworks.com/clients/amp].
32.
WosinskaMarta (2002), “The Economics of Prescription Drug Advertising,” doctoral dissertation, Department of Economics, University of California, Berkeley.
33.
XieYing, and KrishnamurthiLakshman (2004), “The Impact of DTC Advertising and Physician Promotions on Treatment Incidence and Brand Choice Decisions,” working paper, Rutgers Business School, Marketing Department, Rutgers University.
